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Abstract
Aims/hypothesis There is currently insufficient evidence to
recommendalow-proteindietfortype2diabeticpatientswith
diabetic nephropathy. We assessed whether a low-protein diet
could prevent the progression of diabetic nephropathy.
Methods This was a multi-site parallel randomised controlled
trial for prevention of diabetic nephropathy progression
among 112 Japanese type 2 diabetic patients with overt
nephropathy. It was conducted in Japan from 1 December
1997 to 30 April 2006. The participants were randomly
assignedusingacentralcomputer-generatedscheduletoeither
low-protein diet (0.8 g kg
−1day
−1) and normal-protein diet
(1.2 g kg
−1day
−1), and were followed for 5 years. The
participants and investigators were not blinded to the
assignment. The primary outcomes were the annual change
in estimated GFR and creatinine clearance, the incidence of
doubling of serum creatinine and the time to doubling of
baseline serum creatinine.
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DOI 10.1007/s00125-009-1467-8Results The study was completed by 47 (84%) of 56
participants in the low-protein diet group and 41 (73%) of
56 participants in the normal-diet group. During the study
period, the difference in mean annual change in estimated
GFR between the low-protein diet and the normal-protein
diet groups was −0.3 ml min
−1 1.73 m
−2 (95% CI −3.9, 4.4;
p=0.93). The difference in mean annual change in
creatinine clearance between the low-protein diet and the
normal-protein diet groups was −0.006 ml s
−1 1.73 m
−2
(95% CI −0.089, 0.112; p=0.80). A doubling of serum
creatinine was reached in 16 patients of the low-protein
group (34.0%), compared with 15 in the normal-protein
group (36.6%), the difference between groups being −2.6%
(95% CI −22.6, 17.5; p=0.80). The time to doubling of
serum creatinine was similar in both groups (p=0.66).
Conclusions/interpretation It is extremely difficult to get
patients to follow a long-term low-protein diet. Although
in the low-protein group overall protein intake was
slightly (but not significantly) lower, it did not confer
renoprotection.
Clinical trial registration: ClinicalTrials.gov NCT 00448526
Funding: Research grant from the Ministry of Health,
Labour and Welfare of Japan
Keywords Albuminuria.Diabetic nephropathy.eGFR.
Low-proteindiet.Proteinuria
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Introduction
Diabetic nephropathy develops in 40% of patients with
diabetes and, in spite of progress in new treatment for
diabetes and anti-hypertensive drugs, is the leading cause of
end-stage renal disease (ESRD) worldwide [1–3]. Diabetic
nephropathy is also closely associated with higher cardio-
vascular mortality rates [4]. Therefore, additional efforts are
needed to arrest the progression of diabetic nephropathy.
A low-protein diet slows the progression of renal disease
and improves survival in patients with various glomerulo-
pathies, including diabetic kidney disease [5]. Clinically, a
meta-analysis suggested that low-protein diet lowers the
incidence of ESRD or death in patients with non-diabetic
nephropathies [6]. Another meta-analysis of 108 patients
with type 1 diabetes in five studies (mean follow-up
4.5–35 months) showed the benefit of low-protein diet in
slowing the progression of diabetic nephropathy [7].
Indeed, a low-protein diet is recommended as nutritional
management of diabetic nephropathy [8], although there is
insufficient evidence to suggest that such a diet improves
renal dysfunction [9, 10]. The landmark study of non-
diabetic kidney disease, the Modification of diet in renal
disease study (MDRD), also failed to reach a conclusion
regarding the benefits of a low-protein diet in reducing risk
of ESRD or death [11, 12]. Furthermore, extended follow-
up after the MDRD trial also failed to show a significant
benefit of low-protein diet in slowing the development of
ESRD and all-cause mortality [13].
To explore the uncertainties on effectiveness of low-
protein diet, we conducted a randomised controlled trial to
determine the effect of low-protein diet on the progression
of renal dysfunction and albuminuria in type 2 diabetic
patients with overt nephropathy.
Methods
Study design This was a multi-site randomised controlled
trial for prevention of diabetic nephropathy progression
among 112 type 2 diabetic patients, who were aged 30 to
70 years and had overt nephropathy. The trial was
conducted from 1 December 1997 to 30 April 2006. After
a baseline run-in period (3 months), the patients were
monitored for 5 years. The protocol was approved by the
institutional review boards of each centre. All participating
patients provided written, informed consent. Before the
present study, 41 diabetic patients with overt nephropathy
had been randomly assigned to normal protein intake
(n=21) and low protein intake (n=20) groups. This 1 year
feasibility trial was completed by 34 patients. Daily protein
intake in the feasibility study was 1.22±0.25 g kg
−1day
−1
(normal) and 0.92±0.43 g kg
−1day
−1 (low protein) and the
difference was statistically significant (p<0.05). Based on
these data, sample size for the present study was calculated.
To achieve 90% power with a 5% significance level, we
found that least 31 participants per group would be
necessary. To account for drop-out due to trial duration, a
100 participants (50 per group) were planned for analysis.
Participants The participants were Japanese men and
women, aged 30 to 70 years. All had type 2 diabetes
(defined according to World Health Organization criteria)
of at least 5 years duration and were being treated by diet or
by diet plus oral hypoglycaemic agents or insulin injection.
Other inclusion criteria were: (1) urinary protein excretion
more than 1 g/day but less than 10 g/day; (2) urinary
albumin excretion rate of more than 200 µg/min at least
twice in a 1 year period; (3) serum creatinine below
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on normal-protein diet (1.2 g kg
−1 day
−1). Potential partic-
ipants were excluded if they had: type 1 diabetes; other
renal diseases; body weight less than 80% of ideal body
weight; clinically significant illness such as congestive
heart failure, hepatic disease, recent myocardial infarction
and stroke, and urinary tract infection; or if they were being
treated with a low-protein diet (0.8 g kg
−1day
−1) and/or
ACE inhibitors (ACE-I) or angiotensin II receptor blockers
(ARBs). Hypertension was defined as blood pressure
≥140/90 mmHg or use of anti-hypertensive drugs.
Randomisation and intervention During the 3 month screen-
ing period, the participants continued to take a normal-protein
diet (1.2 g kg
−1day
−1) and their usual medications. They
were then randomly assigned at a central location to follow
either a low-protein diet (0.8 g kg
−1day
−1) or a normal-
protein diet (1.2 g kg
−1day
−1) with the appropriate energy
intake for each participant without masking.
The methods of minimisation for allocation were applied
according to age, sex, serum creatinine, estimated GFR
(eGFR), and urinary albumin and protein levels during the
screening period. Both groups were instructed to meet the
registered dietitian for 30 min every 3 months to assess and
counsel dietary issues. After randomisation we followed the
participants for approximately 3.5 years (1–5 years). Every
3 months, all participants completed a 3 day food record to
assess daily protein, energy and sodium intake. For this
purpose, we used the fourth revised and enlarged edition of
Standard tables of food composition in Japan [14]. The
dietary protein intake was also assessed by urinary urea
nitrogen excretion during 24 h urine collection every
3 months, using the formula of Maroni et al. [15]. To
achieve dietary protein goals, dietary regimens were
modified every 3 months or more as needed. The estimated
protein intake during the study represents the mean of all
measurements after randomisation.
Laboratory tests Blood and urine samples were brought to
the central laboratory (SRL, Tokyo, Japan) and each
clinical parameter was measured using the Hitachi 7170
analyzer (Hitachi High-Technologies, Tokyo, Japan) unless
otherwise specified. GFR was estimated using the follow-
ing modified MDRD formula for Japanese participants
[16]: eGFR (ml min
−11.73 m
−2)=175×[serum creatinine
(μmol/l)/88.4]
−1.154×[age (years)]
−0.203×0.741×(0.742 if fe-
male), where serum creatinine estimated by an enzymatic
method was calibrated. Creatinine clearance from a 24 h
timed urine collection was calculated and corrected to a
body surface area of 1.73 m
2. Urinary excretion of protein
and albumin was measured every 3 months in 24 h timed
urine samples using an immunoturbidity assay and a
pyrogallol red–molybdate complex (LX60000; Eiken
Chemical Co., Tokyo, Japan), respectively. Urinary nitro-
gen was measured by an enzymatic ultraviolet method
every 3 months. Blood samples were obtained every
3 months to measure: renal function (blood urea nitrogen,
creatinine, Na, K, Cl, uric acid) by an autoanalyser; lipids
(total cholesterol, triacylglycerol, HDL-cholesterol) by an
enzymatic colorimetric method and a direct inhibition
method, respectively; transferrin by an immunoturbidity
assay (BN-II; Dade Boehring, Marbug, Germany); serum
glucose by a glucose oxidase method; and HbA1c by ion
exchange HPLC (ADAMS A1c HA-8160; Aarkray, Kyoto,
Japan).
Outcomes The primary outcomes were: (1) the annual
change in eGFR and creatinine clearance; (2) the incidence
of doubling of serum creatinine; and (3) the time to
doubling of baseline serum creatinine. The secondary
outcomes included the proportion of patients with ESRD
requiring haemodialysis and the annual changes in urinary
protein and albumin excretion. Quality of life was assessed
annually using the SF-36 [17].
The secondary analysis, which was not based on a
direct comparison of randomised groups, was performed
to assess the biological dose–response relationship be-
tween actual protein intake and progression of type 2
diabetic nephropathy.
Statistical analysis An independent data and safety moni-
toring board monitored the study. The Lan–DeMets alpha
spending-function method was used to adjust for interim
analyses once a year. Four formal interim analyses were
performed during the study period. The p value for one
interim analyses was set at p=0.01. Data handling and trial
management were coordinated centrally by EPS (Tokyo,
Japan).
The mean dietary protein intake between the low- and
normal-protein diet groups was analysed using Wilcoxon’s
rank sum test. Dietary protein intake in the low- and
normal-protein diet groups during the study was analysed
by repeated measures ANOVA.
Analyses of the primary and secondary outcomes were
performed according to the intention-to-treat principle; we
included data from all randomised patients with the
exception of the 24 participants lost or excluded between
randomisation and study termination (Fig. 1). For contin-
uous variables, the mean and standard deviation were
calculated. Because of the skewed deviation, values for
albuminuria and proteinuria are given as medians and
interquartile ranges. In calculating the slopes of the rates of
change of eGFR and creatinine clearance, linear regression
analysis was used and included the data of patients who
reached an endpoint. A minimum of 1 year follow-up with
at least two measurements of serum and urinary creatinine
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analysis. Primary outcome values between groups were
assessed by an analysis of covariance model, with low-
protein diet as a factor and baseline urinary protein, serum
creatinine, HbA1c, systolic blood pressure and daily protein
intake, in addition to age and sex, as covariates. The
incidence of doubling of serum creatinine was compared
with the χ
2 test. The times to doubling of baseline serum
creatinine and its components were compared by Kaplan–
Meier survival curves and the log-rank test. Baseline serum
creatinine was adjusted using Cox proportional hazards
models with terms for the diet assignment. Secondary
outcomes were compared with the χ
2 test (for non-
parametric data) or repeated measures ANOVA (for
continuous data).
In secondary analysis, the differences between
achieved protein intake and renal functions were deter-
mined using Pearson’s correlation coefficient and Spear-
man’s rank/correlation coefficient. To identify the factors
associated with the doubling of serum creatinine, the
potential risk factors such as systolic blood pressure,
protein intake, sodium intake, HbA1c and total cholesterol
were included in the Cox proportional hazards model,
adjusting for sex, age, urinary albumin excretion and
serum creatinine.
All statistical tests were two-sided. For the final
analysis of the primary endpoints and all other endpoints,
a p value of 0.05 or less was considered to indicate
significance. Data were analysed using SAS 8.2 (Statisti-
cal Analysis System, Cary, NC, USA).
Results
Participants The baseline characteristics of the 112 type 2
diabetic participants with nephropathy who underwent
randomisation were similar between low-protein diet and
normal-protein diet groups (Table 1). The study was
completed by 47 of the 56 (84%) participants in the low-
protein diet group and by 41 of the 56 (73%) participants in
the normal-protein diet group (Fig. 1). In both groups, the
reasons for dropping out were: loss of follow-up due to
moving (ten participants); withdrawal of informed consent
(five participants); and less than two measurements of
dietary protein intake and of serum and urinary creatinine
during the study period (nine participants).
Dietary assessment At randomisation, there was no differ-
ence in mean dietary protein intake between the two diet
groupsasassessedbya 3dayfoodrecordanda dietitian(low-
protein 1.0±0.3 vs normal-protein 1.1±0.2 g kg
−1day
−1)a n d
by estimates using 24 h urinary nitrogen excretion (1.0±0.2
vs 1.0±0.2 g kg
−1day
−1, respectively). During the study, the
mean protein intake from the food record was significantly
different between low- and normal-protein intake group
(0.9±0.2 vs 1.1±0.2 g kg
−1day
−1,r e s p e c t i v e l y ,p<0.0001),
while the protein intake derived from 24 h urinary nitrogen
excretion was similar between the two group (1.0±0.2 vs
1.0±0.2 g kg
−1day
−1, respectively, p=0.16). The mean
protein intake estimated by urinary nitrogen excretion in
the low-protein diet group was lower than that in the normal-
protein group during the study period, but the difference was
Assessed for eligibility  (n=124)
Not meeting inclusion criteria, excluded 
(n=12)
Analysed (n=47)
Excluded from analysis  (n=3)
Reasons:
• Less than two measurements of urinary 
nitrogen, serum creatinine
Lost to follow-up  (n=6)
Reasons:
• Withdrew n=2
• Moving n=4
Low-protein diet (n=56)
Lost to follow-up  (n=9)
Reasons:
• Withdrew n=3
• Moving n=6
Normal-protein diet (n=56)
Analysed (n=41)
Excluded from analysis  (n= 6)
Reasons:
• Less than two measurements of urinary 
nitrogen, serum creatinine
112 patients randomly assigned to:
Fig. 1 Design of the trial. Fif-
teen patients were lost during
follow-up because they moved
away or withdrew informed
consent within 1 year of follow-
up. Nine patients were excluded
from analysis because they had
less than two measurements of
urinary nitrogen excretion and
serum creatinine
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significant difference between the two groups based on food
record (p<0.0001) (Fig. 2b).
Primary outcomes The mean annual change in eGFR
was −6.1±6.5 ml min
−1 1.73 m
−2 for the low-protein diet
group, compared with −5.8±5.7 ml min
− 1 1.73 m
−2 for the
normal-protein diet group; the difference between the two
groups was −0.3 ml min
− 1 1.73 m
−2 and not significant
(95% CI −3.9, 4.4; p=0.93). The mean annual change in
creatinine clearance was −0.163±0.159 ml s
−1 1.73 m
−2 for
the low-protein diet group, compared with −0.157±
0.125 ml s
−1 1.73 m
−2 for the normal-protein diet group;
the difference between the two groups was −0.006 ml s
−1
1.73 m
−2 and also not significant (95% CI −0.089, 0.112;
p=0.80). A doubling of serum creatinine was reached in 16
patients of the low-protein diet group (34.0%), as compared
with 15 in the normal-protein diet group (36.6%), with a
difference between the two groups of −2.6% (95%
CI −22.6, 17.5; p=0.80). The time to doubling of serum
creatinine was similar in both groups (p=0.66) (Fig. 3). The
hazard ratio for the doubling of serum creatinine by Cox
regression was 0.42 (95% CI 0.042, 4.22) for the low-
protein diet group.
Secondary outcomes The proportion of patients with ESRD
was 6.4% in the low-protein diet group, compared with
7.3% in the normal-protein diet group, with a difference
between the two groups of −0.9% (95% CI −0.11, 0.10; p=
0.86). During the study period, the level of albuminuria in
the low-protein diet group was not different from that in the
normal-protein diet group (Fig. 4a). The level of proteinuria
was also similar (Fig. 4b).
Associations of achieved protein intake with eGFR and
creatinine clearance The secondary analysis, which was
not based on a direct comparison of randomised groups,
was performed to assess the biological dose–response
relationship between actual protein intake and the progres-
sion of diabetic nephropathy in type 2 diabetes, without
adjustment for other covariates. The lower protein intake,
which was calculated by urinary nitrogen excretion
(Fig. 5a) and the 3 day food record (Fig. 5b), was not
associated with a slower deterioration of GFR. The
correlational analysis using the annual change in creatinine
clearance was also not conclusive with regard to the
efficiency of low-protein diet, as measured by urea nitrogen
excretion (p=0.22) (Fig. 5c) and dietary record (p=0.71)
(Fig. 5d). In the multivariate model, adjusted for systolic
blood pressure, protein and sodium intake, HbA1c and
serum total cholesterol during the study, systolic blood
pressure was independently associated with the doubling of
serum creatinine (Table 2).
Adverse events and quality of life During the study, one
participant of the low-protein diet group died due to
tuberculosis-linked sepsis and one participant of the
normal-protein diet group died due to acute myocardial
infarction. The difference in body weight between baseline
and end of follow-up was 0.9 kg in the low-protein diet
group and 0.2 kg in the normal-diet group, which was not
significantly different between the two groups. During the
study period, there was also no significant difference
between the two groups in total energy (108.8±18.4 vs
113.8±15.9 kJ kg
−1day
−1) and sodium intake (7.7±2.1 vs
7.9±2.0 g/day) as determined from the 3 day food record.
Furthermore, the level of transferrin was not significantly
Variable Low-protein diet (n=56) Normal-protein diet (n=56)
Age (years) 57.5±7.8 56.3±8.7
Male sex, n (%) 33 (58.9) 33 (57.1)
Height (cm) 160.4±8.5 160.7±7.8
Weight (kg) 63.8±10.7 62.9±10.5
Systolic blood pressure (mmHg) 138±21 137±16
Diastolic blood pressure (mmHg) 77±11 77±12
Serum creatinine (μmol/l) 91.9±50.4 98.1±45.1
eGFR (ml min
−1 1.73 m
−2) 63.5±26.9 61.1±23.7
Urinary albumin (μg/min) 488 (214–1,359) 527 (325–1,364)
Urinary protein (g/day) 1.1 (0.4–3.2) 1.2 (0.5–2.9)
HbA1c (%) 7.8±1.5 7.5±1.7
Total cholesterol (mmol/l) 5.7±1.1 5.8±1.3
Triacylglycerol (mmol/l) 1.8±0.9 1.8±0.9
With hypertension (%) 63.0 68.6
Table 1 Baseline characteristics
of the participants
Unless otherwise stated, values
are mean±SD or medians
(interquartile range)
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(p=0.83). There were no significant differences in health-
related quality of life between the two groups during the
study period, as measured by several SF-36 subscales
(physical function, social function, physical role, emotional
role, mental health, energy, pain and general health
perceptions; p>0.1).
Discussion
We found that the low-protein diet was not associated with
a better renal outcome than a normal-protein diet in patients
with type 2 diabetes. Low-protein diet did not slow the rate
of progression of nephropathy as estimated not only by the
incidence of doubling of serum creatinine, but also by the
time to doubling of serum creatinine concentration, com-
pared with the normal-protein diet group. The mean annual
change in eGFR and creatinine clearance was also similar
between the two groups. The secondary analysis, which
assessed the association between the rate of progression of
diabetic nephropathy and the achieved protein intake, also
failed to find a beneficial effect. Based on the time-
dependent Cox proportional hazards model, no renal benefit
of low-protein diet was observed, although systolic blood
pressure significantly influenced the progression of diabetic
nephropathy. We thus interpret these results to indicate that
a low-protein diet is probably not renoprotective in patients
with type 2 diabetic nephropathy.
In a long-term study similar to ours, Pijls et al. reported
that protein restriction is neither feasible nor efficacious
[18], although they had recruited type 2 diabetic patients
with microalbuminuria (30–300 mg/day) and relatively
high albuminuria within the normo-albuminuric range
(albuminuria >20 mg/day or detectable urinary albumin,
i.e. albumin concentration >6.5 mg/l). In contrast, Hansen
et al. performed a 4 year prospective, controlled trial with
concealed randomisation to compare the decline in GFR
and development of ESRD or death in type 1 diabetes
patients with advanced diabetic nephropathy comparable to
our participants [19]. Their usual-protein diet group
consumed 1.02 g kg
−1day
−1 as compared with 0.89 (range
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−1day
−1 in the low-protein diet group, a
protein intake similar to our groups. However, in contrast to
our findings, Hansen et al found that type 1 diabetic
patients suffering from progressive diabetic nephropathy
experienced a beneficial effect of moderately restricted
dietary protein on the development of ESRD or mortality
rates. The discrepancy might be due to the different types of
diabetes and/or use of antihypertensive drugs, with almost
90% of patients in their study taking ACE-I. In our study,
patients were instructed not to take ACE-I and/or ARBs, as
these had not been approved for the treatment of diabetic
nephropathy in Japan when this study was completed.
The prescribed protein intake in the low-protein group in
our study (approximately 0.8 g kg
−1day
−1) resulted in a
mean achieved protein intake of about 1.0 g kg
−1day
−1,a s
estimated by urinary nitrogen excretion, which was not
statistically different from protein intake in the normal-
protein diet. Since diabetic patients have to accept other
restrictions to their diet regimen [4, 8, 20], compliance to an
additional low-protein diet could be reduced. The achieved
level of long-term dietary protein restriction may reflect
everyday life in an outpatient clinic set-up. Therefore, we
cannot directly address the issue of whether the effects of
lower protein intake such as 0.8 g kg
−1day
−1, the amount
recommended in a nutritional statement by the American
Diabetes Association (2008) [8], would be beneficial for
type 2 diabetic patients with nephropathy. Non-adherence
to the prescribed low-protein diet would result in underes-
timation of the true beneficial effect of the low-protein diet
in the present study. However, it is not reasonable to
assume that a lower protein intake equal to or less than
0.8 g kg
−1day
−1 would reduce the risk of progression of
diabetic nephropathy, because the relationship between
achieved protein intake (0.55–1.6 g kg
−1day
−1) and annual
rate of eGFR decline as well as creatinine clearance decline
also failed to produce any benefits for low-protein diet in
our study. The MDRD, moreover, also failed to reach a
conclusion on this issue [11–13]. Indeed, the recent long-
term follow-up of the MDRD provides evidence that even
very low protein diet, supplemented with keto acids and
amino acids, increased the risk of death without the benefit
of delaying progression of kidney diseases [21].
In the present study, we found that systolic blood
pressure, rather than other variables such as blood glucose
control, daily protein intake and sodium intake, played a
major role in accelerating the progression of diabetic
nephropathy during the follow-up period. Our results
suggest that blood pressure control results in inhibition of
progression of diabetic nephropathy [4, 22]. Furthermore,
coexisistence of hypertension and type 2 diabetes is well
known to accelerate the risk not only of development and
progression of diabetic nephropathy, but also of cardiovas-
cular disease outcome [22–25], meaning that control of
high blood pressure is a major protective strategy against
renal and cardiovascular outcomes in patients with diabetic
nephropathy. Indeed, recent guidelines recommend treating
type 2 diabetic patients with antihypertensive drugs, if their
blood pressure is in the high-normal (previously normal)
range (130–139/85–90 mmHg), and sometimes even if
blood pressure is in the normal and/or low prehypertensive
range (120–129/80–85 mmHg) [26, 27].
Although previous experimental data suggested that the
effects of low-protein diet, similar to treatment with an
ACE-I or ARBs, are mediated through blockade of the
renal renin–angiotensin system [28, 29], dietary protein
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Diabetologia (2009) 52:2037–2045 2043restriction in the present study, where patients were not on
ACE-I or ARBs, did not seem to act through the renin–
angiotensin system. At present, adding ACE-I or ARB to
multifactorial intervention could reduce the progression of
diabetic nephropathy, as reported in several studies [30–35].
Interestingly, a recent report by Parving et al. showed that
without restriction of dietary salt or protein, the use of the
renin inhibitor, aliskiren, in combination with an ARB
efficiently reduces urinary albuminuria in diabetic patients
with overt proteinuria [36].
In summary, it is extremely difficult to get patients to
follow a long-term low-protein diet, and although overall
protein intake was slightly (but not significantly) lower, it
did not confer renoprotection. Our data may shed the light
on the dietary management of diabetic nephropathy. One
possible result is that protein restriction may not remain a
main nutritional recommendation in clinical practice,
because we now have a most valuable therapeutic strategy
for reducing progression of diabetic nephropathy as well as
cardiovascular events and mortality rates by using intensive
multifactorial interventions such as lifestyle management,
ACE-I or ARBs, and lipid-lowering drugs, as reported in
the Steno-2 study [32, 33]. Without additional data, we
must continue to base decisions on the current balance of
evidence for and against the efficacy and safety of dietary
protein restriction.
Variable Hazard ratio (95% CI)
a p value
Systolic blood pressure (mmHg) 1.1 (1.02–1.14) 0.012
Protein intake (g kg
−1day
−1) 1.8 (0.07–44.64) 0.73
Sodium intake (g/day) 0.9 (0.72–1.14) 0.41
HbA1c (%) 0.9 (0.59–1.23) 0.49
Total cholesterol (mmol/l) 1.0 (1.0–1.01) 0.49
Table 2 Hazard ratios of factors
associated with the doubling of
serum creatinine
aThe multivariate model was
adjusted for the following base-
line variables: sex, age, urinary
albumin excretion and serum
creatinine
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Fig. 5 Correlation between
achieved protein intake estimat-
ed (a) from urinary nitrogen
excretion and the annual change
in eGFR, and (b) from 3 day
food record and the annual
change in eGFR. c Correlation
between achieved protein intake,
estimated from urinary nitrogen
excretion and (d) from from
3 day food record, and the
annual change in creatinine
clearance. The p value was
calculated using Spearman's
rank correlation coefficient
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